Carboplatin News and Research

RSS
Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).
New method traces primed resistance in cancer via sister cells

New method traces primed resistance in cancer via sister cells

A certain type of chemotherapy found to improve the immune system's ability to fight off bladder cancer

A certain type of chemotherapy found to improve the immune system's ability to fight off bladder cancer

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

Promising new drug target for triple-negative breast cancer identified

Promising new drug target for triple-negative breast cancer identified

New course of treatment with existing drugs for cervical cancer reduces risk of death by 35%

New course of treatment with existing drugs for cervical cancer reduces risk of death by 35%

Short course of induction chemotherapy can reduce cervical cancer relapse and death by 35%

Short course of induction chemotherapy can reduce cervical cancer relapse and death by 35%

NCCN survey shows cancer drug shortages continue despite efforts

NCCN survey shows cancer drug shortages continue despite efforts

Intensity-modulated radiation therapy reduces radiation exposure to heart and lungs in NSCLC patients

Intensity-modulated radiation therapy reduces radiation exposure to heart and lungs in NSCLC patients

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

Osimertinib plus chemotherapy shows significant PFS benefit in advanced EGFR-mutated NSCLC

The potential prognostic role of AhRR and PPP1R3C expression in serous ovarian cancer

The potential prognostic role of AhRR and PPP1R3C expression in serous ovarian cancer

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Patient-derived head and neck cancer organoids could aid the discovery of novel therapies

Patient-derived head and neck cancer organoids could aid the discovery of novel therapies

New anticancer agent activated by ultrasound waves does not have strong side effects

New anticancer agent activated by ultrasound waves does not have strong side effects

Pembrolizumab in combination with chemotherapy improves progression free survival for women with advanced or recurrent endometrial cancer

Pembrolizumab in combination with chemotherapy improves progression free survival for women with advanced or recurrent endometrial cancer

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Study estimates the cost-effectiveness of therapeutic alternatives

Study estimates the cost-effectiveness of therapeutic alternatives

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual